Vitekta Side Effects
Generic Name: elvitegravir
Note: This document contains side effect information about elvitegravir. Some of the dosage forms listed on this page may not apply to the brand name Vitekta.
For the Consumer
Applies to elvitegravir: oral tablet
Along with its needed effects, elvitegravir (the active ingredient contained in Vitekta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Some side effects of elvitegravir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- feeling sad or empty
- lack of appetite
- loss of interest or pleasure
- stomach discomfort, upset, or pain
- thoughts or attempts at killing oneself
- trouble concentrating
- trouble sleeping
- unusual tiredness or weakness
For Healthcare Professionals
Applies to elvitegravir: oral tablet
Very common (10% or more): Increased lipase (14%), diarrhea (up to 13%)
Common (1% to 10%): Abdominal pain, vomiting, nausea, increased serum amylase
Uncommon (0.1% to 1%): Dyspepsia, abdominal distension, flatulence[Ref]
Increased serum amylase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in 6% of patients.
If serum amylase was greater than 1.5 x ULN, lipase was also measured. Increased lipase (grades 3 to 4) has been reported in 14% of patients.[Ref]
Increased total bilirubin (greater than 2.5 x ULN), GGT (greater than 5 x ULN), ALT (greater than 5 x ULN), and AST (greater than 5 x ULN) have been reported in 6%, 3%, 2%, and 2% of patients, respectively.[Ref]
Common (1% to 10%): Increased total bilirubin, increased ALT, increased AST[Ref]
Increased creatine kinase (at least 10 x ULN) has been reported in 6% of patients.[Ref]
Common (1% to 10%): Increased creatine kinase, back pain, arthralgia, pain in extremity
Frequency not reported: Osteonecrosis[Ref]
Hematuria (greater than 75 RBC/high power field) and urine glucose (4+) have been reported in 6% and 4% of patients, respectively.[Ref]
Common (1% to 10%): Hematuria, urine glucose[Ref]
Increased total cholesterol (greater than 300 mg/dL), increased total triglycerides (greater than 750 mg/dL), and hyperglycemia (greater than 250 mg/dL) have each been reported in 5% of patients.[Ref]
Common (1% to 10%): Increased total cholesterol, increased total triglycerides, hyperglycemia[Ref]
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Dizziness, paresthesia, somnolence, dysgeusia[Ref]
Common (1% to 10%): Decreased neutrophils[Ref]
Decreased neutrophils (less than 750/mm3) has been reported in 3% of patients.[Ref]
Suicidal ideation and suicide attempt were reported in patients with history of depression or psychiatric illness.[Ref]
Common (1% to 10%): Depression
Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt, insomnia[Ref]
Common (1% to 10%): Rash[Ref]
Common (1% to 10%): Fatigue[Ref]
Frequency not reported: Autoimmune disorders (e.g., Graves' disease)[Ref]
1. Cerner Multum, Inc. "Australian Product Information." O 0
2. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
4. "Product Information. Vitekta (elvitegravir)." Gilead Sciences, Foster City, CA.
Some side effects of Vitekta may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
More about Vitekta (elvitegravir)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews – Add your own review/rating
- Drug class: integrase strand transfer inhibitor
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.